Fasting blood samples were collected, and serum samples were stored at –20 °C until further use for both groups. Serum gastrin concentrations were measured using the Gastrin RIA Kit II (Dynabot, Tokyo, Japan). Serum PG I and PG II concentrations were determined by radioimmunoassay (Abbott, Tokyo, Japan) for the years 1990 to 1999, chemiluminescent immunoassay (Abbott) from 1999 to 2001, enzyme immunoassay (E-plate test; Eiken, Tokyo, Japan) from 2001 to 2003, and latex agglutination test (L-Z test; Eiken) from 2003 to 2014. PG positivity was defined as serum PG I concentrations of ≤ 70 ng/mL and a PG I/II ratio of ≤ 3.0 [31 –33 (link)]. Serum anti-Hp Abs in the pathology group was determined with the Pyloristat kit (Whittaker Bioproducts, Walkerville, MD, USA) using enzyme-linked immunosorbent assay (ELISA). Serum anti-Hp Abs titers of the endoscopically-evaluated group were evaluated using ELISA (E-plate; Eiken Chemical). The cut-off value for anti-Hp Abs in the endoscopically-evaluated group was 3 U/mL [34 (link), 35 (link)].
E plate test
Manufactured by Eiken Chemical
Sourced in Japan
The E-plate test is a laboratory equipment used to detect the presence and identify specific types of microorganisms in a sample. It provides a standardized method for culturing and analyzing microbial growth.
Automatically generated - may contain errors
3 protocols using e plate test
1
Gastrin, Pepsinogens, and Helicobacter Pylori Evaluation
2
Esophagogastroduodenoscopy for Gastric Conditions
Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients undergoing esophagogastroduodenoscopy for the following indications were eligible for inclusion: 1) screening for gastric cancer; 2) dyspeptic symptoms; 3) surveillance after endoscopic treatment of early gastric cancer; 4) surveillance after endoscopic treatment of NET; and 5) pernicious anemia. Patients were excluded if they had: 1) a history of
H. pylorieradication therapy; 2) anticoagulation therapy or coagulopathy; 3) treatment with nonsteroidal anti-inflammatory drugs or steroids; 4) a history of esophagogastric surgery; or 5) major organ failure.
Patients who met inclusion criteria, did not fulfil exclusion criteria, and gave written informed consent for study participation were tested for serum anti-
H. pyloriantibody (E-plate test, Eiken Chemical, Co, Ltd, Japan) and gastrin levels, then underwent endoscopic examination according to the protocol below. Among them, those who satisfied diagnostic criteria of
H. pylori-naïve,
H. pylori-associated gastritis, and autoimmune gastritis were enrolled for analysis in this study.
+ Expand
Patients undergoing esophagogastroduodenoscopy for the following indications were eligible for inclusion: 1) screening for gastric cancer; 2) dyspeptic symptoms; 3) surveillance after endoscopic treatment of early gastric cancer; 4) surveillance after endoscopic treatment of NET; and 5) pernicious anemia. Patients were excluded if they had: 1) a history of
H. pylorieradication therapy; 2) anticoagulation therapy or coagulopathy; 3) treatment with nonsteroidal anti-inflammatory drugs or steroids; 4) a history of esophagogastric surgery; or 5) major organ failure.
Patients who met inclusion criteria, did not fulfil exclusion criteria, and gave written informed consent for study participation were tested for serum anti-
H. pyloriantibody (E-plate test, Eiken Chemical, Co, Ltd, Japan) and gastrin levels, then underwent endoscopic examination according to the protocol below. Among them, those who satisfied diagnostic criteria of
H. pylori-naïve,
H. pylori-associated gastritis, and autoimmune gastritis were enrolled for analysis in this study.
3
Gastric Mucosa Assessment via Biomarkers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Fasting blood samples were collected from participants, and the serum samples were stored at − 20 °C until use. Serum PG I and PG II levels were measured by radioimmunoassay (Abbott, Tokyo, Japan) from 1990 to 1999, chemiluminescent immunoassay (Abbott) from 1999 to 2001, enzyme immunoassay (E-plate test; Eiken, Tokyo, Japan) from 2001 to 2003, and latex agglutination test (L-Z test; Eiken) from 2003 to 2014. Patients with PG I levels > 70 ng/mL or PG I/PG II levels > 3 ng/mL were considered to have high PG levels [13 (link)]. Serum Hp-Ab titers were evaluated using an enzyme-linked immunosorbent assay (E-plate; Eiken). The cut-off value was set to 3 U/mL [24 (link)]. Using the definition of the ABC method, we classified patients with high PG levels and negative Hp-Ab, high PG levels and positive Hp-Ab, low PG levels and positive Hp-Ab and low PG levels and negative Hp-Ab, into groups A, B, C and D, respectively [13 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!